CA3178633A1 - Compose et composition pour induire une neuroprotection - Google Patents
Compose et composition pour induire une neuroprotectionInfo
- Publication number
- CA3178633A1 CA3178633A1 CA3178633A CA3178633A CA3178633A1 CA 3178633 A1 CA3178633 A1 CA 3178633A1 CA 3178633 A CA3178633 A CA 3178633A CA 3178633 A CA3178633 A CA 3178633A CA 3178633 A1 CA3178633 A1 CA 3178633A1
- Authority
- CA
- Canada
- Prior art keywords
- tetramethyl
- oxo
- oxazaphosphinan
- compound
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2005138A FR3110393B1 (fr) | 2020-05-20 | 2020-05-20 | Compose et composition pour induire une neuroprotection |
| FRFR2005138 | 2020-05-20 | ||
| PCT/FR2021/050929 WO2021234324A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3178633A1 true CA3178633A1 (fr) | 2021-11-25 |
Family
ID=73013493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3178633A Pending CA3178633A1 (fr) | 2020-05-20 | 2021-05-20 | Compose et composition pour induire une neuroprotection |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12611387B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142703B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023531869A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230013116A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116981449A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3178633A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2970378T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR3110393B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021234324A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| FR3163834A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine |
| WO2026003229A1 (fr) | 2024-06-26 | 2026-01-02 | Rest Therapeutics | Derives de fluoroethylnormemantine pour leur utilisation en tant que medicament |
| FR3163835B1 (fr) | 2024-06-26 | 2026-06-26 | Rest Therapeutics | Derives de fluoroethylnormemantine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339070C (zh) * | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| BRPI0516112A (pt) * | 2004-10-15 | 2008-08-26 | Janssen Pharmaceutica Nv | métodos para neuroproteção |
| US20090118376A1 (en) * | 2007-11-02 | 2009-05-07 | Ru-Band Lu | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia |
| FR2935611B1 (fr) | 2008-09-10 | 2010-10-15 | Commissariat Energie Atomique | Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes |
| US20120115943A1 (en) * | 2008-10-01 | 2012-05-10 | National Taiwan University | Composition and method for neuroprotection against excitotoxic injury |
| EP2586436A1 (en) * | 2011-10-31 | 2013-05-01 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor |
| FR3006193B1 (fr) * | 2013-05-29 | 2015-06-19 | Holis Technologies | Nouveaux composes chimiques derives de la memantine et susceptibles de se fixer sur les recepteurs de n-methyl-d-aspartate (nmda) |
| FR3050732B1 (fr) | 2016-05-02 | 2019-06-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nouveaux derives de phosphinolactones et leurs utilisations pharmaceutiques |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| WO2020232246A1 (en) * | 2019-05-15 | 2020-11-19 | The Trustees Of Columbia University In The City Of New York | Compositions and methods against stress-induced affective disorders and their associated symptoms |
-
2020
- 2020-05-20 FR FR2005138A patent/FR3110393B1/fr active Active
-
2021
- 2021-05-20 ES ES21734182T patent/ES2970378T3/es active Active
- 2021-05-20 US US17/924,420 patent/US12611387B2/en active Active
- 2021-05-20 CN CN202180060125.1A patent/CN116981449A/zh active Pending
- 2021-05-20 KR KR1020227044712A patent/KR20230013116A/ko active Pending
- 2021-05-20 EP EP21734182.5A patent/EP4142703B8/fr active Active
- 2021-05-20 CA CA3178633A patent/CA3178633A1/fr active Pending
- 2021-05-20 WO PCT/FR2021/050929 patent/WO2021234324A1/fr not_active Ceased
- 2021-05-20 JP JP2022571216A patent/JP2023531869A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3110393A1 (fr) | 2021-11-26 |
| EP4142703B8 (fr) | 2023-11-22 |
| EP4142703A1 (fr) | 2023-03-08 |
| CN116981449A (zh) | 2023-10-31 |
| EP4142703C0 (fr) | 2023-10-18 |
| WO2021234324A1 (fr) | 2021-11-25 |
| US12611387B2 (en) | 2026-04-28 |
| ES2970378T3 (es) | 2024-05-28 |
| EP4142703B1 (fr) | 2023-10-18 |
| KR20230013116A (ko) | 2023-01-26 |
| FR3110393B1 (fr) | 2022-05-06 |
| JP2023531869A (ja) | 2023-07-26 |
| US20230270695A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4142703B1 (fr) | Composé et composition pour induire une neuroprotection | |
| Zheng et al. | Curcumin ameliorates memory decline via inhibiting BACE1 expression and β-Amyloid pathology in 5× FAD transgenic mice | |
| Wirianto et al. | The clock modulator Nobiletin mitigates astrogliosis‐associated neuroinflammation and disease hallmarks in an Alzheimer’s disease model | |
| Panza et al. | Disease-modifying approach to the treatment of Alzheimer’s disease: From α-Secretase activators to γ-secretase inhibitors and modulators | |
| Lai et al. | Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice | |
| Companys-Alemany et al. | NMDA receptor antagonists reduce amyloid-β deposition by modulating calpain-1 signaling and autophagy, rescuing cognitive impairment in 5XFAD mice | |
| Mancuso et al. | Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before | |
| Panza et al. | Beyond the neurotransmitter-focused approach in treating Alzheimer’s disease: drugs targeting β-amyloid and tau protein | |
| Buendia et al. | Subthreshold concentrations of melatonin and galantamine improves pathological AD-hallmarks in hippocampal organotypic cultures | |
| Weber et al. | Killing two angry birds with one stone: autophagy activation by inhibiting calpains in neurodegenerative diseases and beyond | |
| Zamani et al. | Key mechanisms underlying netrin‐1 prevention of impaired spatial and object memory in Aβ1‐42 CA1‐injected rats | |
| US20200164010A1 (en) | Method for treating dementia | |
| Roy et al. | C-reactive protein: the nexus between inflammation and protein misfolding diseases | |
| Carles et al. | The selective butyrylcholinesterase inhibitor UW‐MD‐95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease | |
| Espinosa-Jiménez et al. | A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet | |
| Wang et al. | PARP16-mediated stabilization of amyloid precursor protein mRNA exacerbates Alzheimer’s disease pathogenesis | |
| Carles et al. | Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease | |
| Joshi et al. | Transient receptor potential channels as an emerging target for the treatment of Alzheimer's disease: Unravelling the potential of pharmacological interventions | |
| Rong et al. | Dual PDE4/10A inhibition restores CREB1 function and enhances neuronal resilience in models of alzheimer's disease | |
| Xie et al. | Acute transcriptomic and epigenetic alterations at T12 after rat T10 spinal cord contusive injury | |
| Zidan et al. | Memantine/Rosuvastatin Therapy Abrogates Cognitive and Hippocampal Injury in an Experimental Model of Alzheimer's Disease in Rats: Role of TGF-β1/Smad Signaling Pathway and Amyloid-β Clearance | |
| Viswanathan et al. | Ubiquilin‑1 Modulates γ‑Secretase-Mediated ε‑Site Cleavage in Neuronal Cells | |
| Hensley et al. | Autophagy modulation by lanthionine ketimine ethyl ester improves long-term outcome after central fluid percussion injury in the mouse | |
| Tan et al. | Anti-Alzheimer therapeutic drugs targeting γ-secretase | |
| Bales et al. | Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer’s disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250423 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250505 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250505 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250715 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250715 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250716 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260311 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260423 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260423 |